CHROMALBIN
LOE Approachingalbumin chromated cr-51 serum
BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHROMALBIN is a radiolabeled serum albumin diagnostic agent containing Chromium-51 used for nuclear medicine imaging studies. It functions as a tracer to visualize blood pool dynamics and assess organ perfusion and function. The product is administered by injection and relies on radioactive labeling rather than traditional pharmacological mechanisms.
LOE Approaching
As a legacy diagnostic product approaching loss of exclusivity with minimal linked job count, career opportunities are likely limited and focused on legacy portfolio management or divestment support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHROMALBIN offers limited career growth opportunities given zero linked job openings and approaching loss of exclusivity. Career relevance is primarily in managing a legacy diagnostic asset through its mature lifecycle phase, focusing on operational efficiency and eventual transition or divestment.
Portfolio ManagerRegulatory Affairs Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.